Dr. Michael Pride, a Pfizer Scientist, Leads a Team Searching For Ways to Improve Diagnosis, Prevention and Treatment of Clostridium difficile Infections

Dr. Pride of Pfizer leads a team that is searching for ways to improve diagnoses & treatment of C. difficile,

Dr. Michael Pride is the Executive Director, Vaccine Research and Development at Pfizer

Challenges, Chance and Looking Forward. Historically, a difficult diagnosis process has posed challenges to treatment for C. difficile infections, as detection is not straightforward. Dr. Pride and his team are working to tackle this issue by developing better ways to diagnose this infection, which will aid efforts to develop a vaccine. Additionally, he is encouraged by recent work that has demonstrated how an antibody can help prevent recurrent diseases, offering insight that an antibody-mediated response, raised by vaccines, may be a way to help reduce a primary episode of a C. difficile infection.

“If our vaccine is successful, we could help have a great impact on global health, reducing morbidity and even mortality worldwide,” he says. “I’m confident in our team, who is working tirelessly so that hopefully no one must suffer from these horrible symptoms again.”

Today, Dr. Pride leads a team of scientists responsible for the development, qualification and validation of various assays that support Pfizer’s vaccine programs.

 

 

Click on the link below to learn more about Dr. Michael Pride’s Work:

http://innovation.org/about-us/innovation-faces/researcher-profiles/michaelpride?utm_source=Twitter&utm_medium=Social&utm_campaign=NCAC&utm_term=02030501050201&utm_content=DrMichaelPride&sf200705754=1